ViiV Announces Expanded Access to Once-a-Day Integrase Inhibitor ... But Activists Are Concerned About Its Potential Misuse
March 7, 2012
The dolutegravir expanded access program (EAP) has been designed to provide free access to Shionogi-ViiV Healthcare's investigational integrase inhibitor, dolutegravir (DTG, S/GSK1349572) in an open-label protocol program to adults living with HIV who have documented raltegravir or elvitegravir resistance, who have limited treatment options, and who require DTG to construct a viable antiretroviral regimen for therapy.
But before you consider the use of this new drug, read the following warning: Activists Advise Caution About Access Program
Who can participate in the dolutegravir EAP (ING114916)?
The dolutegravir EAP is available to adults living with HIV who (Note: Not all inclusion criteria are listed):
Are male or female age 18 years or older (female patients of child-bearing potential should use every precaution to prevent pregnancy)
The dolutegravir EAP is not available to adults living with HIV who (Note: Not all exclusion criteria are listed):
Have estimated creatinine clearance (CrCl) <30 mL/min
*Please note: country specific criteria may also apply.
The dolutegravir EAP is now open and accepting participants in the USA and Canada.
For Europe and the International region, it's expected that the EAP will start to open in March/April 2012 as local regulatory and ethics approvals are obtained.
How to Apply for Participation
For adults living with HIV: Please discuss your possible participation with your healthcare professional. If the EAP is available in your country, check with your healthcare provider if he or she is a participating site. If not, your healthcare provider may contact PAREXEL for further details on how to access the program.
For healthcare professionals treating HIV: If you have an eligible patient(s), please contact PAREXEL at email@example.com for further details about the program.
What Is Dolutegravir?
Dolutegravir (DTG, GSK1349572) is an integrase inhibitor under development as a treatment for HIV-1 infection. Phase III studies to assess the safety and efficacy of dolutegravir in antiretroviral naive and experienced adults living with HIV are currently underway. The safety and efficacy of dolutegravir has not yet been fully established or thoroughly evaluated by regulatory agencies.
This article was provided by Nelson Vergel.
Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)